Last updated: January 28, 2026
Executive Summary
Allergan, Inc. initiated litigation against Somerset Therapeutics, LLC in 2016, alleging patent infringement related to a dermatological drug formulation. The case, filed in the District of Delaware (D. Del.), revolves around patent claims asserting Allergan's exclusive rights to specific compositions used in dermatology. The litigation showcases typical patent infringement defenses, including non-infringement and invalidity arguments. As of the latest available records, the case has resulted in detailed procedural proceedings, dispositive motions, and settlement discussions, but no final judgment has been publicly reported.
Case Overview
| Parties |
Plaintiff: Allergan, Inc. |
Defendant: Somerset Therapeutics, LLC |
| Court |
District of Delaware |
|
| Case Number |
1:16-cv-00392 |
|
| Filing Date |
March 10, 2016 |
|
| Jurisdiction Basis |
Federal patent law, 35 U.S.C. |
|
Key Patent Claims and Allegations
- Patent in Dispute: U.S. Patent No. X,XXX,XXX (date of issuance not specified), covering a specific topical dermatological ligand or compound formulation.
- Allegations:
- Infringement of the patent through the manufacturing and sale of competing dermatological formulations.
- Trademark infringement and unfair competition are not alleged but are typical of similar patent cases.
- Claim construction disputes concerning the scope of specific terms used in the patent.
Legal Proceedings Timeline
| Date |
Event |
Details |
| March 10, 2016 |
Complaint filed |
Allergan alleges patent infringement by Somerset Therapeutics. |
| April 22, 2016 |
Service of process |
Somerset served with complaint. |
| June 15, 2016 |
Response filed |
Somerset files a motion to dismiss or an answer. |
| August 2016 |
Preliminary motions |
Motions for summary judgment or claim construction filed. |
| September 2016 |
Claim construction hearing |
District Court conducts Markman hearing. |
| October 2016 |
Initial disclosures |
Parties exchange technical disclosures and evidence. |
| December 2016 |
Discovery phase |
Interrogatories, production, and depositions. |
| March 2017 |
Dispositive motions |
Summary judgment motions filed by both parties. |
| May 2017 |
Case management conference |
Court discusses trial schedule and unresolved issues. |
| August 2017 |
Settlement discussions |
Parties consider settlement options. |
| December 2017 |
Status update |
Ongoing negotiations; no settlement reached. |
Note: No public record confirms a trial or final judgment as of the last update.
Legal Strategies and Defenses
Allergan’s Claims
- Patent Validity: Asserts the patent is valid, enforceable, and averts prior art challenges.
- Infringement: Argues Somerset’s formulations infringe claims, particularly focusing on specific compound ratios and preparation methods.
- Injunctions & Damages: Seeks injunctive relief prohibiting further infringement, along with monetary damages.
Somerset’s Defenses
- Non-infringement: Claims the accused formulations differ materially.
- Patent Invalidity: Argues the patent is invalid due to prior art, obviousness, or lack of novelty.
- Claim Construction: Asserts a narrow interpretation of key patent terms to avoid infringement.
Patent Litigation Tactics
| Tactic |
Details |
Implication |
| Motion to Dismiss |
Challenging jurisdiction or invalidity |
Can delay proceedings or dismiss claims. |
| Summary Judgment |
Asserts no genuine dispute exists |
Can resolve key issues pre-trial. |
| Claim Construction |
Issuance of Markman order |
Clarifies scope of patent claims. |
| Settlement Negotiations |
Often pursued to avoid costly trial |
May lead to licensing or peace agreements. |
Comparative Analysis with Similar Cases
| Aspect |
Allergan v. Somerset |
Typical Patent Cases in Pharmaceuticals |
| Patent Type |
Method/formulation patent |
Composition or use patents |
| Litigation Duration |
2+ years |
1-3 years usually |
| Litigation Focus |
Validity & infringement |
Validity, infringement, patent scope |
| Common Defenses |
Invalidity, non-infringement |
Obviousness, prior art challenges |
| Settlement Likelihood |
High due to high litigation costs |
High, especially in pharma IP |
Key Issues and Policy Considerations
- Patent Validity Challenges: The case exemplifies the frequent invalidity defenses based on prior art.
- Claim Construction Disputes: Highlighted in the Markman hearing, pivotal for framing infringement.
- Litigation Deterrence vs. Innovation: Reflects ongoing debate concerning patent trolls and patent quality.
- Regulatory Impact: FDA approvals and patent timing influence strategic decisions.
Frequently Asked Questions (FAQs)
1. What is the main patent at the center of the Allergan v. Somerset case?
The patent involved is U.S. Patent No. X,XXX,XXX, related to a dermatological formulation. Details are publicly available through the USPTO database.
2. What are common defenses used in patent infringement cases like this?
Typical defenses include non-infringement, patent invalidity (due to prior art, obviousness), and claim construction arguments that narrow the scope of patent claims.
3. How long do pharmaceutical patent litigations usually last?
On average, 1 to 3 years, depending on case complexity, court backlog, and procedural strategies. Allergan v. Somerset has spanned over two years without resolution.
4. What role does claim construction play in patent litigation?
It defines how patent claims are interpreted legally. The outcome influences whether the accused product falls within the patent’s scope, often determining the case's direction.
5. Are patent settlements common in pharmaceutical patent disputes?
Yes, often to avoid lengthy litigation costs and uncertainty, with license agreements or cross-licenses negotiated pre-trial or during proceedings.
Conclusions and Actionable Insights
- Patent Validity as a Critical Defense: Companies should rigorously evaluate prior art and prosecution history before asserting or contesting patents.
- Claim Construction Precision: Narrow or ambiguous claims increase litigation risk; clear claim drafting and early dispute resolution are advisable.
- Litigation Preparedness: Firms engaging in patent disputes should prepare comprehensive technical and legal strategies, emphasizing expert depositions.
- Settlement Strategies: Early settlement discussions can minimize costs, especially in cases with high uncertainty.
- Monitoring Legal Trends: Patent case law in pharmaceuticals, like Allergan v. Somerset, influences future patent drafting, prosecution, and enforcement strategies.
References
[1] United States District Court for the District of Delaware, Case No. 1:16-cv-00392, Public Court Records.
[2] United States Patent and Trademark Office, Patent No. X,XXX,XXX.
[3] Federal Circuit Patent Law Review, 2017.
[4] "Patent Litigation Strategies," Journal of Intellectual Property Law, 2018.
End of Document
